ArticleGenes & development2015

Inhibition of the autocrine IL-6-JAK2-STAT3-calprotectin axis as targeted therapy for HR-/HER2+ breast cancers.

Ruth Rodriguez-Barrueco et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.